Analysts Pitch Up to 1,000% Returns in Biotech Beyond Covid-19

Analysts Pitch Up to 1,000% Returns in Biotech Beyond Covid-19

(Bloomberg) -- Even a global pandemic hasn’t shaken optimism in one of the most volatile industries.As Covid-19 dominates headlines and sparks billion-dollar share moves, biotech analysts are still pitching massive returns in companies that have nothing to do with developing a drug or vaccine for the disease.Wall Street analysts expect 105 of the 209 members of the Nasdaq Biotechnology Index to double over the next 12 months, data compiled by Bloomberg show. With the index trading just off a record high, many of the Street’s biggest bulls favor companies in areas like women’s health and cancer.Macrogenics Inc., Cytokinetics Inc. and Akebia Therapeutics Inc. are among drugmakers that have doubled so far this year. But the boom-or-bust nature of drug development has burned investors in other stocks, even after analysts piled on praise. Sage Therapeutics Inc.’s failed depression drug study, AnaptysBio Inc.’s eczema flop and Genfit’s NASH woes in recent months have...